Simone van de Sande-Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simone van de Sande-Lee has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Hohl
Universidade Federal de Santa Catarina (UFSC)
11 shared publications - Marcelo Fernando Ronsoni
Department of Medicine Universidade Federal de Santa Catarina Florianópolis Santa Catarina Brazil
10 shared publications - Eric Pasqualotto
Programa de Pós-Graduação em Cirurgia Translacional, Universidade Federal de São Paulo, São Paulo, Brazil
7 shared publications - Matheus Pedrotti Chavez
Universidade Federal de Santa Catarina
6 shared publications - Rafael Oliva Morgado Ferreira
Departamento de Clínica Médica, Universidade Federal de Santa Catarina, Florianópolis, SC, Brasil
6 shared publications - Bruno Halpern
World Obesity Federation, London, UK
5 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Changes in Muscle Strength Following Semaglutide Treatment in Adults: A Systematic Review With Meta‐Analysis of Handgrip Strength
Aims: To systematically review and quantitatively synthesize within‐group changes in skeletal muscle strength following semaglutide treatment in adults. Materials and Methods: This PRISMA 2020 systematic review was registered in PROSPERO (CRD420251185935). MEDLINE, Embase, CENTRAL, LILACS and Google Scholar were searched through 20 August 2026, without language restrictions. Eligible studies included adults treated with semaglutide reporting quantitative skeletal muscle strength outcomes, including handgrip and knee extension strength. Randomized, non‐randomized and uncontrolled before‐after studies were included. The primary meta‐analysis pooled within‐group changes in handgrip strength from baseline to the longest available follow‐up of semaglutide‐only arms using a random‐effects model. Knee extension strength was summarized descriptively. Results: Sixteen reports represented eleven studies, all assessing handgrip strength; one small randomized trial also assessed knee extension strength. Ten studies (660 semaglutide‐treated participants) contributed to the primary meta‐analysis of uncontrolled within‐group changes, showing a nonsignificant pooled handgrip strength change (−0.16 kgf; 95% confidence interval: −1.98 to 1.65), with substantial heterogeneity ( I 2 = 90.8%) and a 95% prediction interval from −5.96 to 5.63 kgf. Duration‐stratified and sensitivity analyses were also nonsignificant. Individual study findings were heterogeneous. Certainty was very low. Conclusions: Available evidence is insufficient to determine whether semaglutide is associated with changes in handgrip strength because the principal synthesis was based on uncontrolled within‐group changes, with very low certainty and significant heterogeneity. These findings do not establish strength preservation or a causal treatment effect. More robust comparative studies with standardized strength assessment and longer follow‐up are needed.
- 19 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Open AccessChanges in Muscle Strength Following Semaglutide Treatment in Adults: A Systematic Review With Meta‐Analysis of Handgrip Strength
Aims: To systematically review and quantitatively synthesize within‐group changes in skeletal muscle strength following semaglutide treatment in adults. Materials and Methods: This PRISMA 2020 systematic review was registered in PROSPERO (CRD420251185935). MEDLINE, Embase, CENTRAL, LILACS and Google Scholar were searched through 20 August 2026, without language restrictions. Eligible studies included adults treated with semaglutide reporting quantitative skeletal muscle strength outcomes, including handgrip and knee extension strength. Randomized, non‐randomized and uncontrolled before‐after studies were included. The primary meta‐analysis pooled within‐group changes in handgrip strength from baseline to the longest available follow‐up of semaglutide‐only arms using a random‐effects model. Knee extension strength was summarized descriptively. Results: Sixteen reports represented eleven studies, all assessing handgrip strength; one small randomized trial also assessed knee extension strength. Ten studies (660 semaglutide‐treated participants) contributed to the primary meta‐analysis of uncontrolled within‐group changes, showing a nonsignificant pooled handgrip strength change (−0.16 kgf; 95% confidence interval: −1.98 to 1.65), with substantial heterogeneity ( I 2 = 90.8%) and a 95% prediction interval from −5.96 to 5.63 kgf. Duration‐stratified and sensitivity analyses were also nonsignificant. Individual study findings were heterogeneous. Certainty was very low. Conclusions: Available evidence is insufficient to determine whether semaglutide is associated with changes in handgrip strength because the principal synthesis was based on uncontrolled within‐group changes, with very low certainty and significant heterogeneity. These findings do not establish strength preservation or a causal treatment effect. More robust comparative studies with standardized strength assessment and longer follow‐up are needed.
- 18 February 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 3335-3343
Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta‐analysis
Aim: To evaluate the effects of tirzepatide on physical function in adults with overweight or obesity. Methods: We searched PubMed, Embase, and the Cochrane Library up to July 20, 2025 for randomized controlled trials (RCTs) comparing once‐weekly tirzepatide 10 or 15 mg with placebo and reporting validated physical function outcomes. Primary endpoints were changes from baseline in the 36‐Item Short Form Health Survey (SF‐36) physical function domain and in the Impact of Weight on Quality of Life‐Lite Clinical Trials (IWQOL‐Lite‐CT) physical function subscale. Random‐effects models were used to calculate pooled mean differences (MD) with 95% confidence intervals (CI). Heterogeneity was assessed with I 2 statistics. Results: Six RCTs comprising 4531 participants, of whom 2802 underwent tirzepatide treatment were included. Tirzepatide significantly improved physical function compared with placebo, both in SF‐36 physical function (MD 2.26 points; 95% CI, 1.76–2.76; I 2 = 99.8%; p < 0.001) and IWQOL‐Lite‐CT physical function (MD 10.10 points; 95% CI, 8.61–11.60; I 2 = 99.8%; p < 0.001). Subgroup analyses by dose demonstrated consistent benefits for both 10 and 15 mg groups. The overall certainty of evidence, rated by GRADE, was moderate due to risk of bias and inconsistency across studies. Conclusions: Tirzepatide 10 and 15 mg once weekly significantly improve patient‐reported physical function in adults with overweight or obesity. These findings suggest tirzepatide enhances perceived physical capacity and quality of life, although the extremely high between‐study heterogeneity limits the interpretability of pooled estimates and warrants cautious interpretation.
- 18 February 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 3335-3343
Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta‐analysis
Aim: To evaluate the effects of tirzepatide on physical function in adults with overweight or obesity. Methods: We searched PubMed, Embase, and the Cochrane Library up to July 20, 2025 for randomized controlled trials (RCTs) comparing once‐weekly tirzepatide 10 or 15 mg with placebo and reporting validated physical function outcomes. Primary endpoints were changes from baseline in the 36‐Item Short Form Health Survey (SF‐36) physical function domain and in the Impact of Weight on Quality of Life‐Lite Clinical Trials (IWQOL‐Lite‐CT) physical function subscale. Random‐effects models were used to calculate pooled mean differences (MD) with 95% confidence intervals (CI). Heterogeneity was assessed with I 2 statistics. Results: Six RCTs comprising 4531 participants, of whom 2802 underwent tirzepatide treatment were included. Tirzepatide significantly improved physical function compared with placebo, both in SF‐36 physical function (MD 2.26 points; 95% CI, 1.76–2.76; I 2 = 99.8%; p < 0.001) and IWQOL‐Lite‐CT physical function (MD 10.10 points; 95% CI, 8.61–11.60; I 2 = 99.8%; p < 0.001). Subgroup analyses by dose demonstrated consistent benefits for both 10 and 15 mg groups. The overall certainty of evidence, rated by GRADE, was moderate due to risk of bias and inconsistency across studies. Conclusions: Tirzepatide 10 and 15 mg once weekly significantly improve patient‐reported physical function in adults with overweight or obesity. These findings suggest tirzepatide enhances perceived physical capacity and quality of life, although the extremely high between‐study heterogeneity limits the interpretability of pooled estimates and warrants cautious interpretation.
- Open Access
- 21 January 2026
- Published by Associação Catarinense de Medicina in Arquivos Catarinenses de Medicina
- Vol. 54 (2) , 58-65
DEPRESSÃO EM PACIENTES COM DIABETES MELLITUS TIPO 2: UMA REVISÃO NARRATIVA
A depressão em pessoas com diabetes mellitus tipo 2 (DM2) é muito prevalente e está relacionada a uma maior dificuldade no controle e enfrentamento do diabetes, o que torna fundamental a triagem e o manejo adequado dessa condição. O presente estudo tem por objetivo realizar uma revisão narrativa dos estudos publicados sobre a epidemiologia, fisiopatologia, impacto clínico, metabólico e psicossocial, triagem e tratamento da depressão em pessoas com DM2. Foram observadas altas taxas de comorbidade entre depressão e DM2, com uma relação bidirecional entre as duas condições, explicada por mecanismos biológicos e psicossociais compartilhados. Os fatores associados à maior prevalência de depressão no diabetes foram sexo feminino, menor escolaridade, diagnóstico recente do diabetes, baixa atividade física e uso de insulina. Quanto aos impactos da depressão no DM2, observou-se dificuldade de adesão ao tratamento, pior controle glicêmico, maior risco de complicações e mortalidade, e redução da qualidade de vida. No que tange ao rastreio, a triagem rotineira tem sido recomendada, utilizando ferramentas validadas. Entre os tratamentos, diversas modalidades de intervenção, incluindo abordagens psicossociais e farmacológicas, estão associadas a uma melhora importante dos sintomas depressivos e do controle do diabetes.
- 21 January 2026
- Published by Associação Catarinense de Medicina in Arquivos Catarinenses de Medicina
- Vol. 54 (2) , 58-65
Open AccessDEPRESSÃO EM PACIENTES COM DIABETES MELLITUS TIPO 2: UMA REVISÃO NARRATIVA
A depressão em pessoas com diabetes mellitus tipo 2 (DM2) é muito prevalente e está relacionada a uma maior dificuldade no controle e enfrentamento do diabetes, o que torna fundamental a triagem e o manejo adequado dessa condição. O presente estudo tem por objetivo realizar uma revisão narrativa dos estudos publicados sobre a epidemiologia, fisiopatologia, impacto clínico, metabólico e psicossocial, triagem e tratamento da depressão em pessoas com DM2. Foram observadas altas taxas de comorbidade entre depressão e DM2, com uma relação bidirecional entre as duas condições, explicada por mecanismos biológicos e psicossociais compartilhados. Os fatores associados à maior prevalência de depressão no diabetes foram sexo feminino, menor escolaridade, diagnóstico recente do diabetes, baixa atividade física e uso de insulina. Quanto aos impactos da depressão no DM2, observou-se dificuldade de adesão ao tratamento, pior controle glicêmico, maior risco de complicações e mortalidade, e redução da qualidade de vida. No que tange ao rastreio, a triagem rotineira tem sido recomendada, utilizando ferramentas validadas. Entre os tratamentos, diversas modalidades de intervenção, incluindo abordagens psicossociais e farmacológicas, estão associadas a uma melhora importante dos sintomas depressivos e do controle do diabetes.
- Open Access
- 28 November 2025
- Vol. 69 (6) , e250547
Response to the letter to the editor: Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.
- 28 November 2025
- Vol. 69 (6) , e250547
Open AccessResponse to the letter to the editor: Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.
- Open Access
- 14 November 2025
- Published by Universidade do Estado do Rio de Janeiro in DEMETRA: Alimentação, Nutrição & Saúde
- Vol. 20, e84778
Níveis séricos de vitamina D estão correlacionados com o colesterol de indivíduos com diabetes mellitus tipo 2 e excesso de peso
Introdução: A vitamina D (25OHD) exerce importante papel no metabolismo dos glicídios e lipídios; entretanto, sua deficiência é frequentemente encontrada em distúrbios metabólicos. Torna-se necessário identificar como os níveis séricos de 25OHD se correlacionam com esses indicadores em indivíduos com diabetes mellitus tipo 2 (DM2) e excesso de peso. Objetivo: Analisar a correlação entre a 25OHD e os indicadores de composição corporal, antropométricos e bioquímicos de indivíduos com DM2 e excesso de peso. Métodos: Estudo transversal conduzido no Hospital Universitário de Florianópolis/SC em indivíduos com DM2 e excesso de peso. A composição corporal foi determinada por absorciometria de raio-x de dupla energia; os dados antropométricos aferidos por técnicas padronizadas; e os biomarcadores analisados por amostra sérica. A correlação entre a 25OHD e os desfechos foi verificada com o uso da correlação de Spearman. Resultados: 20 indivíduos com idades entre 35 e 75 anos, sendo 55% do sexo feminino. Constataram-se compartimentos musculares preservados de acordo com o índice de massa muscular apendicular e elevado percentual de gordura em ambos os sexos. Cinquenta por cento dos indivíduos apresentaram deficiência de vitamina D e 75% utilizavam suplementação. Observou-se correlação inversamente proporcional entre a 25OHD e o colesterol total (r= -0.52 e p valor= 0.02) e não HDL-c (r= -0.47 e p valor= 0.04). Conclusão: Há associação entre os níveis de 25OHD e o perfil lipídico de indivíduos com DM2 e excesso de peso, evidenciando uma correlação inversa.
- 14 November 2025
- Published by Universidade do Estado do Rio de Janeiro in DEMETRA: Alimentação, Nutrição & Saúde
- Vol. 20, e84778
Open AccessNíveis séricos de vitamina D estão correlacionados com o colesterol de indivíduos com diabetes mellitus tipo 2 e excesso de peso
Introdução: A vitamina D (25OHD) exerce importante papel no metabolismo dos glicídios e lipídios; entretanto, sua deficiência é frequentemente encontrada em distúrbios metabólicos. Torna-se necessário identificar como os níveis séricos de 25OHD se correlacionam com esses indicadores em indivíduos com diabetes mellitus tipo 2 (DM2) e excesso de peso. Objetivo: Analisar a correlação entre a 25OHD e os indicadores de composição corporal, antropométricos e bioquímicos de indivíduos com DM2 e excesso de peso. Métodos: Estudo transversal conduzido no Hospital Universitário de Florianópolis/SC em indivíduos com DM2 e excesso de peso. A composição corporal foi determinada por absorciometria de raio-x de dupla energia; os dados antropométricos aferidos por técnicas padronizadas; e os biomarcadores analisados por amostra sérica. A correlação entre a 25OHD e os desfechos foi verificada com o uso da correlação de Spearman. Resultados: 20 indivíduos com idades entre 35 e 75 anos, sendo 55% do sexo feminino. Constataram-se compartimentos musculares preservados de acordo com o índice de massa muscular apendicular e elevado percentual de gordura em ambos os sexos. Cinquenta por cento dos indivíduos apresentaram deficiência de vitamina D e 75% utilizavam suplementação. Observou-se correlação inversamente proporcional entre a 25OHD e o colesterol total (r= -0.52 e p valor= 0.02) e não HDL-c (r= -0.47 e p valor= 0.04). Conclusão: Há associação entre os níveis de 25OHD e o perfil lipídico de indivíduos com DM2 e excesso de peso, evidenciando uma correlação inversa.
- Open Access
- 14 October 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
2025 Brazilian Evidence-based Guideline on the Management of Obesity and Prevention of Cardiovascular Disease and Obesity-Associated Complications: A Position Statement by Five Medical Societies
- 14 October 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
Open Access2025 Brazilian Evidence-based Guideline on the Management of Obesity and Prevention of Cardiovascular Disease and Obesity-Associated Complications: A Position Statement by Five Medical Societies
- Open Access
- 13 October 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (09) , e20250621
Diretriz Brasileira Baseada em Evidências de 2025 para o Manejo da Obesidade e Prevenção de Doenças Cardiovasculares e Complicações Associadas à Obesidade: Uma Declaração de Posicionamento de Cinco Sociedades Médicas
- 13 October 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (09) , e20250621
Open AccessDiretriz Brasileira Baseada em Evidências de 2025 para o Manejo da Obesidade e Prevenção de Doenças Cardiovasculares e Complicações Associadas à Obesidade: Uma Declaração de Posicionamento de Cinco Sociedades Médicas
- Open Access
- 1 January 2025
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 69 (5) , 1-35
Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials
Objective: This study aimed to evaluate the efficacy and safety of selective estrogen receptor modulators (SERMs), specifically clomiphene and enclomiphene, in treating men with functional hypogonadism. Materials and methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials comparing SERMs with placebo, testosterone (T) gel, or human chorionic gonadotropin (hCG), up to July 2024. The primary endpoints were total testosterone (TT), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). Weighted mean differences [...] Abstract Objective: This study aimed to evaluate the efficacy and safety of selective estrogen receptor modulators (SERMs), specifically clomiphene and enclomiphene, in treating men with functional hypogonadism. Materials and methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials comparing SERMs with placebo, testosterone (T) gel, or human chorionic gonadotropin (hCG), up to July 2024. The primary endpoints were total testosterone (TT), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). Weighted mean differences
- 1 January 2025
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 69 (5) , 1-35
Open AccessClomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials
Objective: This study aimed to evaluate the efficacy and safety of selective estrogen receptor modulators (SERMs), specifically clomiphene and enclomiphene, in treating men with functional hypogonadism. Materials and methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials comparing SERMs with placebo, testosterone (T) gel, or human chorionic gonadotropin (hCG), up to July 2024. The primary endpoints were total testosterone (TT), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). Weighted mean differences [...] Abstract Objective: This study aimed to evaluate the efficacy and safety of selective estrogen receptor modulators (SERMs), specifically clomiphene and enclomiphene, in treating men with functional hypogonadism. Materials and methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials comparing SERMs with placebo, testosterone (T) gel, or human chorionic gonadotropin (hCG), up to July 2024. The primary endpoints were total testosterone (TT), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). Weighted mean differences
- Open Access
- 1 January 2025
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 69 (1) , 1-11
Care of patients with obesity in the Emergency Department: a joint position statement from the Brazilian Association of Emergency Medicine (ABRAMEDE) and the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO)
This document presents a joint position statement from the Brazilian Association of Emergency Medicine (ABRAMEDE) and the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) regarding the management of patients with obesity in the Emergency Department. It aimed to provide recommendations for healthcare professionals and policymakers to ensure the provision of appropriate care for patients with obesity, considering their unique needs and the challenges that arise in emergency settings. The position statement addresses key issues such [...] ABSTRACT This document presents a joint position statement from the Brazilian Association of Emergency Medicine (ABRAMEDE) and the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) regarding the management of patients with obesity in the Emergency Department. It aimed to provide recommendations for healthcare professionals and policymakers to ensure the provision of appropriate care for patients with obesity, considering their unique needs and the challenges that arise in emergency settings. The position statement addresses key issues such
- 1 January 2025
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 69 (1) , 1-11
Open AccessCare of patients with obesity in the Emergency Department: a joint position statement from the Brazilian Association of Emergency Medicine (ABRAMEDE) and the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO)
This document presents a joint position statement from the Brazilian Association of Emergency Medicine (ABRAMEDE) and the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) regarding the management of patients with obesity in the Emergency Department. It aimed to provide recommendations for healthcare professionals and policymakers to ensure the provision of appropriate care for patients with obesity, considering their unique needs and the challenges that arise in emergency settings. The position statement addresses key issues such [...] ABSTRACT This document presents a joint position statement from the Brazilian Association of Emergency Medicine (ABRAMEDE) and the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) regarding the management of patients with obesity in the Emergency Department. It aimed to provide recommendations for healthcare professionals and policymakers to ensure the provision of appropriate care for patients with obesity, considering their unique needs and the challenges that arise in emergency settings. The position statement addresses key issues such
- Open Access
- 2 December 2024
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e240422
Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM), [...] ABSTRACT Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM),
- 2 December 2024
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e240422
Open AccessPharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM), [...] ABSTRACT Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM),